J Korean Ophthalmol Soc.  2008 Nov;49(11):1729-1736.

Efficacy of Vitamin A-containing Lubricant in Dry Eye Syndrome Evaluated by Impression Cytology

Affiliations
  • 1Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea. ckjoo@catholic.ac.k

Abstract

PURPOSE
To evaluate the therapeutic effect of topical vitamin A-containing lubricant in dry eye patients.
METHODS
Three hundred eyes of 150 patients with dry eye (Schirmer I test< or =10 mm, BUT< or =10 seconds) were divided into three groups. Preservative-containing artificial tears, preservative-free artificial tears, and vitamin A-containing lubricant were administrated to Groups 1, 2, and 3, respectively (N=50). We evaluated and checked symptom scores, tear film breakup time (tBUT), Schirmer I test results, corneal fluorescein stain scores, and impression cytology immediately and at 1, 2, and 3 months after treatment.
RESULTS
Mean tBUT and goblet cell density significantly increased from 5.06+/-1.25 to 6.76+/-1.21 sec and from 125.62+/-61.52 to 192.86+/-69.38 cell/mm2, respectively, after 2 months in group 3 (P<0.05). Impression cytology grade significantly decreased from 2.14+/-0.38 to 1.67+/-0.41 after 2 months in group 3 (P<0.05). The Schirmer I test score significantly increased from 9.12+/-4.15 to 12.83+/-0.96 mm, and the corneal stain score decreased from 2.13+/-0.95 to 1.18+/-0.68 after 3 months in group 3 (P<0.05).
CONCLUSIONS
The improvement of symptoms and the stabilization of tear films and ocular surfaces suggested that treatment with vitamin A-containing lubricant for dry eye was effective.

Keyword

Dry eye; Impression cytology; Vitamin A-containing lubricant

MeSH Terms

Dry Eye Syndromes
Eye
Fluorescein
Goblet Cells
Humans
Ophthalmic Solutions
Tears
Vitamins
Fluorescein
Ophthalmic Solutions
Vitamins

Figure

  • Figure 1 . Change from the baseline in blurred vision symptom scale. O-HU=Lacure®; O-RFR=Refresh plus®; O-viva=Viva®; Mean value±standard error. Graded on a symptom scale from 0 to 4. Statistically significant decreases of blurred vision from baseline at all follow-up visits in group 3 are shown (* P<0.05 by Mann-Whitney U Test).

  • Figure 2 . Change from the baseline in tear breakup time. O-HU=Lacure®; O-RFR=Refresh plus®; O-viva Viva®; Mean value±standard error. The increase from the baseline in tear breakup time (sec) was statistically significant in group 3 at 2 months and 3 months. (* P<0.05 by paired-T-test).

  • Figure 3 . Change from baseline in Schirmer I test. O-HU: Lacure®; O-RFR: Refresh plus®; O-viva: Viva® Mean value± standard error. The increase from baseline in Schirmer test value (mm) was statistically significant in groups 3 at 3 months. (* P<0.05 by paired-T-test).

  • Figure 4 . Change from the baseline in impression cytology grade. O-HU=Lacure®; O-RFR=Refresh plus®; O-viva=Viva®; Mean value±standard error. The decrease from the baseline in impression cytology grade was statistically significant in group 3 at 2 months and 3 months. (* P<0.05 by Mann- Whitney U Test).

  • Figure 5 . Example of impression cytology after 3 months in each group. Group 1=Lacure®; Group 2=Refresh plus®. Group 3= Viva®. There was no significant improvement in impression cytology after 3 months in group 1 (A=Stage 3-initial; B=Stage 3-after 3 months) and group 2 (C=Stage 3-initial; D=Stage 3-after 3 months). But improvement of impression cytology was shown after 3 months in group 3 (E=Stage 3-initial, F=Stage 2-after 3 months) (×100, PAS-hematoxylin stain).

  • Figure 6 . Change from baseline in goblet cells density. O-HU: Lacure®, O-RFR: Refresh plus®, O-viva: Viva®; Mean value±standard error. The increase from baseline in goblet cells density (cell/mm2) was statistically significant in group 3 at 2 months and 3 months. (* P<0.05 by paired-T-test).

  • Figure 7 . Change from the baseline in corneal stain score. O-HU=Lacure®; O-RFR=Refresh plus®; O-viva=Viva®; Mean value±standard error. The decrease from baseline in corneal stain score was statistically significant in group 3 at 3 months. (* P<0.05 by Mann-Whitney U Test).


Reference

References

1. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: A twenty-five-years review. Cornea. 2000; 19:644–9.
2. Nelson JD, Havener VR, Cameron JD. Cellulose acetate impressions of the ocular surface. Dry eye states. Arch Ophthalmol. 1983; 101:1869–72.
Article
3. Tseng SC, Hirst LW, Maumenee AE, et al. Possible mechanisms for the loss of goblet cells in mucin-deficient disorders. Ophthalmology. 1984; 91:545–52.
Article
4. Kobayashi TK, Tsubota K, Takamura E, et al. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. Ophthalmologica. 1997; 211:358–61.
Article
5. Hatchell DL, Sommer A. Detection of ocular surface abnormalities in experimental vitamin A deficiency. Arch Ophthalmol. 1984; 102:1389–93.
Article
6. Ubels JL, Osgood TB, Foley KM. Vitamin A is stored as fatty acyl esters of retinol in the lacrimal gland. Curr Eye Res. 1988; 7:1009–16.
Article
7. Ubels JL, MacRae SM. Vitamin A is present as retinol in the tears of humans and rabbits. Curr Eye Res. 1984; 3:815–22.
Article
8. Tseng SC. Staging of conjunctival squamous metaplasia by impression cytology. Ophthalmology. 1985; 92:728–33.
Article
9. Tseng SC, Maumenee AE, Stark WJ, et al. Topical retinoid treatment for various dry-eye disorders. Ophthalmology. 1985; 92:717–27.
Article
10. Varma SD, Richards RD, Morris SM. Ocular damage by hematoporphyria and light. In vitro studies with the lens. Lens Res. 1988; 3:319–33.
11. Tseng SC. Topical retinoid treatment for dry eye disorders. Trans Ophthalmol Soc U K. 1985; 104:489–95.
12. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000; 107:631–9.
13. Kunert KS, Tisdale AS, Gilpson IK. Goblet cell number and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002; 120:330–7.
14. Oh HJ, You IC, Yoon KC. Changes of Tear Parameters after Using Cyclosporine A in Dry Eye with Thyroid Ophthalmopahty. J Korean Ophthalmol Soc. 2007; 48:630–6.
15. Kinoshita S, Kiorpes TC, Friend J, Thoft RA. Goblet cell density in ocular surface disease: a better indicator than tear mucin. Arch Ophthalmol. 1983; 101:1284–7.
16. Molinari JF, Rengstorff R. Management of soft lens induced GPC with vitamin A aqueous drops. Contact lens J. 1988; 16:169–70.
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr